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Objective: Cerebral hyperperfusion is a life-threatening syndrome that can occur in patients with chronically
hypoperfused cerebral vasculature whose normal cerebral circulation was re-established after carotid endarterec-
tomy or angioplasty. We sought to determine whether the abrupt restoration of perfusion to the brain after left
ventricular assist device (LVAD) implantation produced similar syndromes.
Methods:We studied the role of increased systemic flow after LVAD implantation on neurologic dysfunction
in 69 consecutive HeartMate XVE LVAD (Thoratec, Pleasanton, Calif) recipients from October 2001 through
June 2006. Neurologic dysfunction was defined as postoperative permanent or transient central change in
neurologic status, including confusion, focal neurologic deficits, visual changes, seizures, or coma for more
than 24 hours within 30 days after LVAD implantation.
Results: We found that 19 (27.5%) patients had neurologic dysfunction, including encephalopathy (n ¼ 11),
coma (n¼ 3), and other complications (n¼ 5). The multivariate analysis showed that an increase in cardiac index
from the preoperative baseline value (relative risk, 1.33 per 25% cardiac index increase; P¼ .01) and a previous
coronary bypass operation (relative risk, 4.53; P ¼ .02) were the only independent predictors of neurologic dys-
function. Reduction of left ventricular assist device flow in 16 of the 19 symptomatic patients led to improvement
of symptoms in 14 (87%) patients.
Conclusions: Our findings showed that normal flow might overwhelm cerebral autoregulation in patients with
severe heart failure, suggesting that cerebral hyperperfusion is possible in recipients of mechanical circulatory
support with neurologic dysfunction.
CARDIOTHORACIC TRANSPLANTATIONLeft ventricular assist devices (LVADs) have been success-
fully used in patients with end-stage heart failure, either as
a bridge to transplantation or as an alternative to transplanta-
tion or destination therapy. Although LVAD implantation
has become an accepted therapy for patients with advanced
heart failure, themorbidities associatedwith use of the device
have been an ongoing concern. In particular, postoperative
neurologic complications are relatively common, and some-
times they can lead to devastating complications that pre-
clude a transplantation and result in very poor quality of life.
According to the 2005 Report of the Mechanical Circula-
tory Support Device Database, serious neurologic complica-
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various types of mechanical circulatory support pumps im-
planted at 60 international centers.1 In LVAD recipients
the reported incidence of postoperative neurologic compli-
cations varies by center and pump type, as described in detail
by Pae and colleagues.2 In the largest published single-cen-
ter studies, the stroke incidence ranges from 3% in 226
HeartMate XVE LVAD (Thoratec, Pleasanton, Calif) recip-
ients3 and 17% in 288 Novacor LVAD (WorldHeart, Oak-
land, Calif) recipients4 to as high as 57% in 23 recipients
of the totally implantable LionHeart LVAD (Arrow Interna-
tional, Inc, Reading, Pa).2
Most postoperative neurologic complications, including
the most serious events, such as strokes, occur within the
first few days or weeks after LVAD implantation.1-4 Hence
the incidence of perioperative neurologic complications af-
ter LVAD surgery exceeds by several times the relatively
small 1.9% incidence noted after other cardiac operations,5
suggesting an association between the development of
neurologic complications and either the device itself or the
operation needed to implant it. The exact mechanism by
which LVAD implantation contributes to the development
of symptoms is not completely understood. Most of the
literature assumes that clinically significant neurologic
events result either from device-related thromboembolism,6urgery c April 2009
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XAbbreviations and Acronyms
CI ¼ cardiac index
CT ¼ computed tomographic
IABP ¼ intra-aortic balloon pump
LVAD ¼ left ventricular assist device
ND ¼ neurologic dysfunction
PRES ¼ posterior reversible encephalopathy
syndrome
RR ¼ relative risk
operation-related air embolism,7 or hemorrhage.8 Autopsies
of patients with fatal neurologic complications, however, did
not always reveal evidence of cerebral embolism.6,7
In this retrospective review we investigated whether an
abrupt increase in systemic blood flow could contribute to
LVAD-related neurologic dysfunction (ND) in patients
with end-stage heart failure. We hypothesized that restora-
tion of normal cardiac output in this patient group might re-
sult in cerebral dysfunction, which is similar to the cerebral
hyperperfusion syndrome observed in some patients after ca-
rotid artery endarterectomy or angioplasty.9 This syndrome
is believed to result from the inability of chronically hypoper-




From October 30, 2001, through June 13, 2006, a total of 69 patients un-
derwent HeartMate XVE LVAD implantation at the University of Minne-
sota Medical Center. We excluded from our analysis recipients of other
types of HeartMate LVADs, Novacor LVADs, and axial flow devices, as
well as those who required biventricular temporary support before device
implantation. The institutional board review approved the study, and all pa-
tients provided informed consent to use their clinical data for this study.
Study Design
Because of the possibility of delayed impairment of cerebral autoregula-
tion up to 28 days after increase of cerebral flow reported after carotid end-
arterectomy,10 in this study we investigated the relationship between
systemic bloodflow andNDwithin the firstmonth after LVAD implantation.
Preoperative clinical data. The following clinical data were avail-
able on the day of the operation: patient characteristics and body surface
area; cause of heart failure; history of cardiovascular events (including car-
diac arrest, myocardial infarction, previous sternotomies, and coronary ar-
tery bypass surgery); history of other comorbidities (including stroke,
diabetes, or renal dysfunction); laboratory data; left ventricular ejection frac-
tion; and details on medical or device therapy for heart failure (including the
use of intravenous inotropes, mechanical circulatory support with an intra-
aortic counterpulsation balloon pump [IABP] and mechanical ventilation).
Neurologic dysfunction. We defined perioperative neurologic dys-
function (ND) as a change in neurologic status, including confusion, focal
neurologic deficits, visual changes, seizures, or coma, for more than 24
hours within 30 days after LVAD implantation, which is consistent with
previously described criteria of cerebral hyperperfusion syndrome.9
Hemodynamic changes. Preoperative cardiac output wasmeasured
on the day of hospital admission and on the day of LVAD surgery with theThe Journal of Thoracic and Cause of a Swan–Ganz catheter and was calculated from the Fick equation. Af-
ter LVAD surgery, the Swan–Ganz catheter was removed. Cardiac output
was recorded from the flow displayed on the device monitor at the time
of the neurologic event, on the third postoperative day, and on postoperative
day 30 or day of hospital discharge, whichever came first. The cardiac index
after LVAD implantation was calculated by dividing the device-recorded
flow (liters per minute) by the patient’s body surface area.
LVAD Surgery
All recipients of LVAD as a bridge to transplantation underwent a com-
plete workup to assess their transplantation candidacy, including carotid
and lower-extremity arterial Doppler studies, pulmonary function tests, co-
lonoscopy, a neuropsychiatric evaluation, and an evaluation by a social
worker. Patients whose LVADs were intended as destination therapy un-
derwent the same workup. History of stroke or neurologic injury was not
a contraindication to LVAD implantation as long as the patient had recov-
ered sufficiently from the neurologic injury, the underlying cause had been
corrected, and the risks for stroke recurrence were low. All studied patients
had carotid Doppler ultrasonographic analysis performed before LVAD in-
sertion or, in case of emergency implantation, after LVAD insertion to min-
imize significant intracranial or extracranial cerebral disease. Also, head
computed tomographic (CT) analysis was performed in 4 patients who
had previous strokes.
LVAD implantation was performed after achievement of general anes-
thesia, with continuous hemodynamic monitoring. Either preperitoneal or
intraperitoneal LVAD implantation was performed through a medial ster-
notomy. Cardiopulmonary bypass was instituted after full heparinization
by means of aortic and right atrial cannulation. Only mild hypothermia
was used during the operation (>32C). The LVAD inflow cannula was se-
cured to the left ventricular apex, and the outflow graft was anastomosed to
the ascending aorta. The driveline of the LVAD was usually tunneled out
through a right upper quadrant incision. Intraoperative transesophageal
echocardiographic analysis was used to confirm the evacuation of air
from the cardiac chambers. The operative field was flooded by carbon diox-
ide to reduce the collection of air inside the heart. Standard maneuvers to
evacuate air included filling the heart with blood and ventilating the lungs,
along with hand pumping of the LVAD. As the patient was weaned off car-
diopulmonary bypass, the LVAD pump was activated with the patient in
a steep Trendelenburg position to reduce the risk of cranial air embolism.
Once the patient was hemodynamically stable with adequate LVAD flow,
protamine was used for reversal of heparin. Appropriate inotropes and va-
sopressors were administered, as necessary, to maintain hemodynamic sta-
bility and to optimize right ventricular function. Postoperatively, the only
routine antithrombotic therapy was aspirin (325 mg/d). Warfarin was used
only if there were indications for its use, such as pre-existing atrial fibrilla-
tion or the presence of a mitral mechanical valve prosthesis.
Statistical Analysis
Preoperative clinical data and hemodynamic changes before and after
LVAD implantation were associated with the end point by using univariate
analysis to identify risk factors associated with perioperative ND in LVAD
recipients. In patients with ND, we compared the hemodynamic measure-
ments at the time of the neurologic event with those of patients who did
not have ND by postoperative day 30 or the day of hospital discharge,
whichever came first. All continuous variables were treated as such, with
the exception of recipient age and body surface area, which were stratified
by their means. The risk factors found to be significant by means of univar-
iate analysis at a P value of less than .10 were then entered into the logistic
regression model at a P value of less than .05.10 The figure showing a rela-
tionship between the increase in cardiac index (CI) and the predicted prob-
ability of postoperative ND was derived from the logistic regression model.
The goodness of fit of this model was measured with the Hosmer–Leme-
show statistic.11 Differences between groups were examined by using c2
or Student’s t tests. Values are reported as means  the standard deviation.rdiovascular Surgery c Volume 137, Number 4 1013
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The baseline characteristics and hemodynamic severity of
heart failure for 69 patients (Tables 1 and 2) were obtained
on the day of admission for LVAD implantation. Most
patients were male (85%), were older than 50 years
(71%), and had ischemic cardiomyopathy (58%). All
patients had severe heart failure, as evidenced by a mean
left ventricular ejection fraction of 17.0%  6.3%, systolic
blood pressure of 95.7 11 mmHg, cardiac index of 1.73
0.4 L $ min1 $ kg2, and pulmonary capillary wedge pres-
sure of 23.8  6.3 mm Hg. On the day of admission, all pa-
tients were maintained on continuous intravenous inotropic
support, 6 of whom were supported with an IABP. After the
decision was made to proceed with LVAD implantation, we
electively placed the IABP the day before the operation in
another 58 patients, so that on the day of LVAD implanta-
tion, 64 (92.7%) patients were supported with an IABP
(mean IABP support time, 1.6 days; range, 12 hours to 7
days).
LVAD Implantation
LVAD implantation was performed on an emergency ba-
sis in 10 (14.5%) patients who were in cardiogenic shock;
the remaining 59 patients were scheduled for elective or
TABLE 1. Baseline patient characteristics (n ¼ 69)
Male sex, n (%) 59 (85.5)
Age (y), mean  SD 54.3  10.7
White, n (%) 65 (94.2)
Body surface area 2 m2, n (%) 21 (30.4)
Medical history
Ischemic cardiomyopathy, n (%) 40 (58.0)
Myocardial infarction, n (%) 26 (37.7)
Cardiac arrest, n (%) 12 (17.4)
Sternotomy, n (%) 24 (34.8)
Coronary artery bypass surgery, n (%) 22 (31.9)
Diabetes mellitus, n (%) 25 (36.2)
Renal disease, n (%) 12 (17.4)
Stroke, n (%) 4 (5.8)
Laboratory results
International normalized ratio, mean  SD 1.32  0.28
White blood count (3 103/mL), mean  SD 9.1  3.0
Hemoglobin (mg/dL), mean  SD 11.9  1.8
Platelet count (3 103/m L), mean  SD 217.9  66.7
Serum sodium (mg/dL), mean  SD 135.3  4.3
Blood urea nitrogen (mg/dL), mean  SD 35.8  22.4
Serum creatinine (mg/dL), mean  SD 1.5  0.6
Total bilirubin (mg/dL), mean  SD 1.5  1.2
Albumin (g/mL), mean  SD 3.4  0.7
Aspartate aminotransferase (U/mL), mean  SD 162.2  428.5
Alanine aminotransferase (U/mL), mean  SD 141.1  353.5
SD, Standard deviation.1014 The Journal of Thoracic and Cardiovascular Ssemielective surgical intervention. At the time of LVAD im-
plantation, coronary artery bypass surgery was performed in
16 patients, and a patent foramen ovale was closed in 7 pa-
tients. The mean cardiopulmonary bypass time was 154.4
minutes (range, 89–323 minutes).
30-Day Outcomes of LVAD Surgery
Survival and hospital discharge. For the purpose of this
analysis, all 69 patients were followed from the day of
LVAD implantation until postoperative day 30 or the day
of hospital discharge, whichever came first, for a mean fol-
low-up of 23.5 days (range, 6–31 days). During the fol-
low-up period, 35 (51%) patients were discharged home,
26 (38%) remained hospitalized, 5 (7%) underwent a heart
transplantation, 2 (3%) died, and 1 (1%) underwent LVAD
explantation. Six (8.7%) patients required implantation of
a right ventricular assist device after LVAD implantation.
Cardiac index after LVAD implantation. The mean CI
increased from 1.73  0.4 L $ min1 $ m2 on the day of ad-
mission to 2.3  0.3 L $ min1 $ m2 on the third postoper-
ative day and to 2.36 0.3 L $min1 $m2 on postoperative
day 30 or the day of hospital discharge. In 42% of LVAD
recipients, CI increased by more than 50%.
Patients With Versus Without ND
Of the 69 studied patients, 19 (27.5%) had ND postoper-
atively, and in 13 (68%) of these patients, ND occurred
within 2 weeks of surgical intervention (mean time to the on-
set of symptoms was 12 days), as shown in Table 3.
Baseline characteristics and severity of heart failure.
Patients with ND were more likely to be older than 50 years
(89.5% with ND vs 64% without ND, P¼ .05) and to have
undergone a previous sternotomy (52.6% with ND vs 28%
without ND, P ¼ .09). Of note, 22 (92%) of 24 of patients
with previous sternotomies underwent coronary artery by-
pass surgery. There were no significant differences between
the 2 groups (with vs without ND) in terms of patient sex,
history of cardiovascular disease, comorbidities, or labora-
tory markers of renal and hepatic function and of coagulation
TABLE 2. Hemodynamic severity of heart failure on the day of
admission (n ¼ 69)
Left ventricular ejection fraction (%), mean  SD 17.0  6.3
Systolic blood pressure (mm Hg), mean  SD 95.7  11.0
Mean arterial pressure (mm Hg), mean  SD 70.4  10.6
Heart rate (beats/min), mean  SD 92.8  14.3
Stroke volume (mL), mean  SD 39.6  12.6
Cardiac output (L/min), mean  SD 3.59  0.96
Cardiac index (L $ min1 $ m2), mean  SD 1.73  0.4
Systolic pulmonary pressure (mm Hg), mean  SD 51.7  13.3
Pulmonary capillary wedge pressure (mm Hg), mean  SD 23.8  6.3
Central venous pressure (cm H2O), mean  SD 14.2  5.3
SD, Standard deviation.urgery c April 2009
Lietz et al Cardiothoracic TransplantationTABLE 3. Clinical symptoms, cardiac index, and computed tomographic results in LVAD recipients with neurologic dysfunction (n ¼ 19)
Cardiac index, L $ min1 $ m2








of head At time of event After event
Improvement of
symtoms
1 10 Coma Yes Ventricular hemorrhage 1.91 (19.4) 1.91 (19.7) No
2 3 Coma, seizure Yes Left frontal infarct 2.89 (70.4) 1.91 (12.5) No
3 30 Left hemiparesis Yes Negative 2.75 (83.4) 2.25 (49.8) Yes
4 17 Left hemiparesis Yes Negative 2.90 (107) 2.50 (78.6) Yes
5 3 Left hemiplegia Yes Negative 3.02 (77.7) 2.24 (31.7) Yes
6 12 Left hemiparesis No Negative 2.86 (50.4) 1.97 (3.7) Yes
7 25 Encephalopathy No Not done 2.89 (60.5) 2.44 (35.8) Yes
8 25 Encephalopathy No Not done 2.80 (86.7) 2.50 (66.7) No
9 8 Confusion No Not done 2.92 (94.7) 2.22 (47.7) Yes
10 6 Confusion No Not done 3.42 (184.9) 2.52 (110.8) Yes
11 16 Confusion No Negative 3.20 (100.2) 2.72 (69.9) Yes
12 26 Confusion No Not done 2.39 (32.5) 2.74 (52.3) Yes
13 7 Confusion No Negative 2.48 (147.8) 1.95 (94.7) Yes
14 11 Confusion No Not done 3.72 (96.1) 2.40 (26.4) Yes
15 1 Agitation No Negative 2.59 (99.2) 2.31 (78.1) Yes
16 10 Confusion, seizure No Negative 2.68 (57.4) 2.67 (57.4) Yes
17 1 Seizure No Negative 2.18 (26.7) 2.01 (17.2) Yes
18 6 Partial vision loss and
confusion
No Negative 3.04 (32.2) 2.44 (6.3) Yes
19 8 Loss of vision in left eye No Negative 2.81 (75.7) 2.59 (62.2) YesT
Xabnormalities. We also found no significant differences in
terms of hemodynamic measures of severity of heart failure.
Hemodynamic measures. Increases in CI, stroke volume,
and mean arterial pressure after LVAD implantation were
stratified by development of ND in Figure 1. There were
no significant differences between the groups (with vs with-
out ND) except at the time of the neurologic event: CIs were
significantly higher in patients with ND compared with
those in control subjects assessed on postoperative day 30
or the day of hospital discharge (mean CI, 2.8 L $ min1 $
m2 with ND vs 2.4 L $ min1 $ m2 without ND; P ¼
.002). The LVAD settings at the time of the event were
more likely to be set in an automatic mode in patients with
ND (52.6% in patients with ND vs 18% in patients without
ND, P ¼ .004). CI increase of more than 50% from the pre-
operative baseline value was found in 15 (79%) of 19 pa-
tients with ND.
Risk Factors for ND
Using logistic regression analysis, we identified 2 inde-
pendent predictors of postoperative ND: an increase of CI
from preoperative baseline values (relative risk [RR], 1.33;
[95% confidence interval, 0.99–1.78] per 25% increase of
CI, P ¼ .01) and history of coronary bypass surgery (RR,
4.53 [95% confidence interval, 1.4–14.7]; P ¼ .02). The
Hosmer–Lemeshow goodness-of-fit test indicated that the
logistic regression model was a good fit (P ¼ .90). The cor-The Journal of Thoracic and Crelation between the predicted probability of ND after LVAD
implantation and the increase in CI derived from the above
model is shown in Figure 2. There was a direct relationship
between the risk of ND and increase in CI in all studied
patients, although those who previously underwent coronary
bypass surgery appeared to be at an overall higher risk. The
correlation between the observed incidence of ND in the
studied cohort and the increase of CI is shown in Figure 3.
Risk factors found significant by means of univariate
analysis at a P value of less than .05 that did not enter the
final model included patient age of greater than 50 years
(RR, 4.8; P ¼ .04) and body surface area of 2 m2 or less
(RR, 2.8; P¼ .06). No other parameters correlated by means
of univariate analysis with ND, including patient sex; cause
of heart failure; history of myocardial infarction or cardiac
arrest; history of other comorbidities, including stroke, dia-
betes, or renal dysfunction; emergency LVAD implantation;
measures of hemodynamic severity of heart failure at the
time of admission and on the day of the operation; preoper-
ative laboratory data; cardiopulmonary bypass time; or de-
vice mode or rate.
Reduction in CI and Recovery From ND
Development of ND prompted reduction of LVAD flow
in 16 (84%) of the 19 patients (Table 3 and Figure 4). The
mean CI was reduced from 2.81  0.41 to 2.33  0.28 L
$ min1 $ m2 (P<.001). The LVAD settings were changed
to fixed mode in 11 patients with ND whose settings were inardiovascular Surgery c Volume 137, Number 4 1015
Cardiothoracic Transplantation Lietz et alFIGURE 1. Comparisons of cardiac index (A), stroke volume (B), and mean arterial pressure (C) in patients with and without neurologic dysfunction within
30 days after left ventricular assist device (LVAD) implantation are shown. Hemodynamics were assessed on the day of admission, the day of LVAD surgery,
postoperative day 3, and postoperative day 30 or the day of hospital discharge, whichever came first. Asterisks indicate statistical difference between patients
with and without neurologic dysfunction.T
Xautomatic mode at the time of their neurologic event. Re-
duced LVAD flow and CI correlated with the improvement
of ND (Figure 4), with clinical improvement or resolution by
48 hours and without negative consequences to patients. Of
the 16 patients whose LVAD flow was reduced, 14 (87.5%)
experienced resolution of ND (Table 3). Of 3 patients whose
LVAD settings were not changed, 2 spontaneously recov-
ered and 1 continued to deteriorate. In the 2 patients who re-
covered, the CI was noted to decrease from the time of the
event from 2.75 to 2.4 L $min1 $m2, whereas in the patient
whose condition continued to deteriorate, CI remained un-
changed at 1.9 L $ min1 $ m2.1016 The Journal of Thoracic and Cardiovascular SDISCUSSION
In a retrospective case series we found that of 69 patients
with advanced heart failure who received the HeartMate
XVE LVAD, 19 (27%) had ND within 30 days after
LVAD surgery. We also demonstrated a monotonic relation-
ship between the probability of postoperative ND and the in-
crease in CI after LVAD implantation. Our results therefore
suggest an association between ND and an excessive in-
crease in systemic blood flow. At the time of the neurologic
event, the CI in nearly 80% of affected patients increased
by greater than 50% from preoperative baseline values.
The temporal association between decrease of flow andurgery c April 2009
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Xresolution or improvement of symptoms suggests that ND
might be a potentially preventable or perhaps reversible con-
dition if related to cerebral hyperperfusion.
Although there are no published data quantifying cerebral
flow in patients with advanced heart failure referred for
LVAD implantation, it is likely that cerebral perfusion is se-
verely impaired in this cohort given previous data showing
abnormal cerebral blood flow in patients with heart fail-
ure.12,13 Results of recent studies with intracranial Doppler
studies14 and radionuclide angiographic analysis15 have
consistently demonstrated that in an ambulatory population
of patients with New York Heart Association class III/IV
heart failure, the baseline cerebral blood flow was reduced
by at least 19% to 31%, thus contributing to the frequently
seen cognitive impairment in these patients.16
Because cerebral flow in LVAD candidates is probably
markedly impaired, it is possible that an abrupt restoration
of normal cardiac output after device implantation could
overwhelm cerebral autoregulation, which is similar to that
described in patients with severe internal carotid artery ste-
nosis who had ND after carotid artery endarterectomy or an-
gioplasty.9,17,18 Those patients’ symptoms ranged frommild
cognitive impairment to life-threatening intracranial hemor-
rhage, brain edema, and coma. The mechanism thought re-
sponsible for their complications was failure of the
severely hypoperfused vasculature to respond to the rapidly
increasing perfusion pressures.19,20
The abrupt restoration of high-output state after LVAD
surgery and the accompanying postoperative ND might
therefore constitute a model of whole-brain cerebral hyper-
perfusion. Our study showed that restoration of normal sys-
temic flow after LVAD implantation in patients with severe
heart failure was associated with a mean 42% increase in CI.
FIGURE 2. Relationship between the increase of cardiac index after left
ventricular assist device implantation and the predicted probability of post-
operative neurologic dysfunction depicted by the history of previous coro-
nary bypass surgery.The Journal of Thoracic and CInterestingly, the systemic blood pressure did not signifi-
cantly increase with the increase in CI, and MAP was not
a risk factor for ND, suggesting the probable primary role
of systemic blood flow rather than blood pressure in this
condition.
Most of the postoperative neurologic complications in the
19 affected patients were mild and included nonfocal symp-
toms involving patient cognition and affect: 12 had confu-
sion or encephalopathy, and 2 became temporarily blind.
Our results are consistent with those of studies of patients
who had cerebral reperfusion syndrome after carotid endar-
terectomy or angioplasty,9,17,18 most of whom had nonfocal
symptoms consistent with perfusion abnormalities in border
zones.
It is important to note, however, that brain hyperperfusion
can be a potentially life-threatening condition. Devastating
complications with excessive LVAD flow, including severe
brain edema and hemorrhage, were previously reported by
Boyle and coworkers21 in 3 patients receiving HeartMate
VE LVADs at our institution. At the time of the neurologic
event, LVAD flow in all 3 of these patients was set at greater
than 5 L/min. In our current study 6 patients had severe
symptoms, including coma (n¼ 2) and hemiparesis or hemi-
plegia (n ¼ 4). In 5 of those patients, LVAD flow exceeded
the 50% increase in CI from the preoperative baseline
values; only 1 patient was found to have had an embolic
stroke in imaging studies.
Of note, the term cerebral hyperperfusion syndrome has
also been applied to conditions that involve an excessive in-
crease in cerebral flow in the course of hypertensive enceph-
alopathy20 or posterior reversible encephalopathy syndrome
(PRES), which can develop in the presence of neurotoxins,
such as cyclosporine.22 In our study, however, we found no
significant association between systemic blood pressure
and ND. There is one case of ND in a child after LVAD im-
plantation in which researchers attributed symptoms to
FIGURE 3. Observed incidence of postoperative neurologic dysfunction
depicted by the increase in cardiac index after left ventricular assist device
implantation.ardiovascular Surgery c Volume 137, Number 4 1017
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XFIGURE 4. The reduction, before and after the neurologic event, in cardiac index (A) and percentage increase in cardiac index (B) in the 19 patients with
neurologic dysfunction is shown. The red line indicates patients whose neurologic dysfunction improved or resolved after systemic flow was reduced. Black
line, Patients whose neurologic dysfunction did not improve.PRES23; of our 13 patients receiving LVADswho underwent
CT analysis of the head, however, none were found to have
radiographic evidence of PRES. Thus our results point to res-
toration of normal blood flow in severely hypoperfused cir-
culation as the most likely mechanism contributing to ND.
It is important to note that advanced age and increased
atherosclerosis burden might render these patients particu-
larly vulnerable to the added effects of excess flow after
LVAD insertion. Increased turbulence in the ascending aorta
and aortic arch might increase atheroembolic risk, and previ-
ously unrecognized intracranial vascular disease might, in
the setting of high flow, cause ND because of worsening
of pre-existing, small-vessel, silent infarction or microhe-
morrhage. We show that LVAD recipients with coronary
atherosclerosis and previous coronary bypass surgery were
at substantially higher risk of postoperative ND. History of
coronary bypass surgery was an independent risk factor
for ND from that conferred by increased CI, suggesting
that device flow might need to be titrated with greater scru-
tiny in older patients with coexisting atherosclerotic disease.
LIMITATIONS
Our study has several limitations. First, because of its retro-
spective nature, transcranialDoppler and brain perfusion stud-
ies were not performed after LVAD implantation, and
therefore we have no direct measurements of cerebral blood
flow at the time of ND. We made the general assumption
that the device-generated systemic flowwas an accurate mea-
sure of cardiac output. We were not able to explain what ac-
counted for the excessive increase of systemic flow at the
time of the neurologic event. Most of the patients with ND
had their devices set in anautomaticmode,which theoretically
should adjust stroke volume to sensed inflow andmaintain the
systemic flow unchanged. The role of device-generated in-
crease of pressure over time (Dp/Dt) was not studied. This
study only examined recipients of HeartMate XVE LVADs,
and these resultsmight not apply to recipients of other devices.
Second, most symptomatic patients did not have formal
neurologic evaluation, and no specific neuropsychological1018 The Journal of Thoracic and Cardiovascular Sutests were given to determinewhich of the spectrum of symp-
toms improved best or most rapidly with reduction of device
flow. Imaging was limited to CT scanning of the head be-
cause the presence of the LVAD excluded use of more sensi-
tive radiographic measurement, such as magnetic resonance
imaging. The CT scanning was done acutely, perhaps limit-
ing its sensitivity to detect ischemic stroke. To avoid bias as-
sociated with a nonuniform workup of ND, we included in
this study all patients with neurologic complications, regard-
less of the results of subsequent clinical evaluation with im-
aging or laboratory tests. Thus the strength of the relationship
between ND and a change in CI might be underestimated.
Third, although postoperative vasodilation might be an
important contributor to cerebral hyperperfusion and auto-
nomic failure, the role of the postoperative use of vasodila-
tors, such as angiotensin-converting enzyme inhibitors,
nitrates, milrinone, inhaled nitric oxide, and infection, bleed-
ing, and vasodilation syndrome, which are often seen in the
postoperative period after LVAD implantation, were not
studied. We were also not able to assess in all patients sys-
temic vascular resistance to explain whether high device
flow was related to systemic vasodilation. We also did not
account for other metabolic disarrangements, which could
contribute to encephalopathy.
Finally, 2 of 3 patients whose LVAD flow was not de-
creased did demonstrate spontaneous resolution of their
ND, and therefore it is possible that some of ND syndromes
in the 16 patients whose LVAD output was decreased might
have also resolved. It is also not yet known whether patients
who demonstrated ND, even transiently, have different long-
term outcomes either on the device or after heart transplan-
tation.
CONCLUSION
In this retrospective series we found an association be-
tween an increase of blood flow after LVAD implantation
and the development of ND. The manner in which cere-
bral hyperperfusion can contribute to postoperative ND
in LVAD recipients could not be definitively explainedrgery c April 2009
Lietz et al Cardiothoracic Transplantationin this observational study. Because cerebral hyperperfu-
sion might be a potentially preventable and/or reversible
condition, prospective studies, including direct measure-
ments of cerebral blood flow and formal neurologic and
neurocognitive evaluation, are necessary to better under-
stand the role of cerebral hyperperfusion in ND after
LVAD implantation.
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